NovaDX - Quality Laboratory Services for Today’s Clinician
We offer state-of-the-art technology to diagnose small fiber neuropathy and multiple menu options for fungal and bacterial pathogens
At NovaDX, it is our goal to facilitate in faster reporting times and better outcomes for patients. Our services can reduce overall healthcare costs, unnecessary surgeries and treatments, and improve patient care.
Education & Research
- Specializing in you – the physician. You specialize in your patients; we specialize in you. That’s why you can count on us to deliver the best product and specialized education.
- We offer in-office and staff training for the biopsy procedure, packaging, and shipment.
- We offer comprehensive education modules for both patients and healthcare professionals.
- Interested in ENFD testing to assess the progression of neuropathy and the response to your treatments, we are happy to help use ENFD testing as a measure of outcome on clinical trials.
Epidermal Nerve Fiber Density (ENFD)
- Skin biopsy for Epidermal Nerve Fiber Density (ENFD) testing is a reliable tool for diagnosing small-fiber neuropathy (SFN).
- The sensitivity of skin biopsy in diagnosing small fiber neuropathy has been reported to be 88%.
- This is in comparison to 54% for the clinical examination, and 49% for quantitative sensory testing (1).
- The specificity of the test is 98% (1).
- Many diseases are associated with SFN such as diabetic neuropathy, alcoholic neuropathy, medication-induced neuropathy, fibromyalgia, and others -> see our education module!
- Skin biopsy is a safe procedure with minimal discomfort that allows somatic fibers carrying temperature and pain sensation to be differentiated from autonomic fibers.
- Loss of epidermal nerve fibers correlates with increased severity of neuropathy and a higher risk of developing neuropathic pain.
- Skin nerve fibers are able to regenerate, and their regrowth rate could be a marker of early axonal damage in patients at risk of developing peripheral neuropathy.
- A skin biopsy can be repeated in close proximity to a previous biopsy in order to assess the progression of neuropathy and the response to neuroprotective treatments and can be used as a measure of outcome in clinical trials.